Resources
About Us
Home Report
Store
China Microarray Market
China Microarray Market Size, Share, Forecast, & Trend Analysis by Product (Consumables [Microarray Kits {DNA (cDNA, Oligo), Protein}], Instruments, Software, Services), Application (Drug Discovery, Research, Diagnostics), End User— Forecast to 2031
Report ID:MRHC - 1041321 Pages: 109 Sep-2024 Formats*: PDF Category: Healthcare Delivery: 2 to 4 HoursThe China Microarray Market was valued at $479.8 million in 2023. This market is expected to reach $910.4 million by 2031 from an estimated $518.2 million in 2024, at a CAGR of 8.4% during the forecast period from 2024 to 2031.
China Microarray Market Size & Forecast
The growth of the China microarray market is driven by expanding research applications of microarrays, increasing genomics and proteomics research, the rising prevalence of cancers and genetic disorders, and increasing R&D investments by the pharma and biotech stakeholders. However, the market growth is restrained by the expensive nature of microarrays over other genetic testing approaches and the increasing adoption of next-generation sequencing technologies. Moreover, the growing adoption of personalized medicines is expected to generate growth opportunities for market stakeholders. The low sensitivity and correctness of microarrays pose a challenge to the growth of the market.
China Microarray Market Growth Drivers
Increasing Research Applications of Microarrays
Microarray technology involves the binding of an array of millions of nucleic acid fragments to a solid surface, which is generally referred to as a chip. A DNA or RNA sample is then added to the chip in order to initiate complementary base pairing when the immobilized fragments on the chip produce light through fluorescence that is detected using a specialized device. Microarray technology allows genomic analysis without sequencing and greatly reduces the cost of performing experiments across the fields of biology and biomedicine. Initially, microarray technology was only used to measure gene expression or quantify certain small molecules. However, the advancements in microarray technology are making it a fast and reliable solution for various applications, such as biomarkers and drug discovery.
Research applications of microarray include clinical trials and drug discoveries for various purposes, such as gene expression, detection of DNA sequences, studying gene mutations, and the presence of certain biomarkers. It can be used as a genomic tool to study and compare different features of the genome based on different diseases and conditions. Due to the study of genomics and data acquired using the technology, population-based studies can also be carried out.
Click here to: Get Free Sample Pages of this Report
Rising Prevalence of Cancers and Genetic Disorders
Cancer is a major cause of death and a prominent obstacle to improving life expectancy around the world. According to GLOBOCAN, in China, the number of new cancer cases in 2022 was 4.8 million, which is expected to reach 7.1 million by 2045. Thus, the increasing number of cancer cases is expected to boost the adoption of microarrays in clinical settings. Microarray applications in oncology research range from basic drug discovery and translational research to patient testing, clinical trials, and population studies.
Apart from cancer, China also shares a significant burden of rare genetic disorders across the world. Congenital disabilities in children have been a major factor contributing to the country’s disease burden. The government currently subsidizes screening of 12 types of congenital disabilities. As per a report published in the International Journal of Environmental Research and Public Health in July 2022, China has a high prevalence of congenital disabilities of nearly 5.6%, and it is estimated that nearly 800,000 to 1,200,000 people children every year are found with malformations, which includes more than 2,500,000 malformation cases.
For this, certain chromosomal diagnostic arrays are being used to test individuals for unexplained developmental delay/intellectual disability (DD/ID), autism spectrum disorders (ASDs), or multiple congenital anomalies (MCA).
China Microarray Market Trends
Use of Microarrays in Forensics
Microarray is a laboratory technique used in the high-throughput analysis of many biological molecules, such as DNA, RNA, proteins, or antibodies, in a single experiment. Microarrays play an important role in the detection of Biological Warfare Agents (BWAs) which are microorganisms or toxins produced by the organisms and are dispersed by people to spread diseases in a community. Microarrays can be used for the fast, sensitive, and simultaneous identification of these agents. The current application of microarrays is the use of a Bead Array Counter (BARC), which is a multi-analyte biosensor that uses DNA hybridization, magnetic microbeads, and giant magnetoresistive (GMR) sensors to identify and detect BWAs.
Furthermore, microarrays play an important role in forensics to identify suspects and missing people by analyzing evidence to analyze evidence from crime scenes, such as degraded samples, determining geographic origins, and analyzing mixtures that can be helpful during the investigation. The growing demand for DNA-based evidence in forensics is a notable trend that is expected to have a positive impact on the adoption of microarray for forensic applications.
Growing Use of 3D Printed Microarrays
There has been a growing trend of 3D printing in the healthcare sector. One such use of 3D printing is microarray printing. Microarray bioprinting refers to printing cells that are encapsulated in hydrogels and use automated liquid dispensing tools or robots such as microarray spotters. These spotters are used to make microarray chips. This technology deposits cDNA probes onto a microscope slide or any other substrate. It has various advantages such as physiologically relevant cells grown in 3D, miniaturization of cell-based assays, reduced use of raw materials life primary human cells obtained from patients, and ultrahigh-throughput capability of testing cell culture conditions.
One of the major applications that uses 3D printed microarrays is drug delivery systems. The transdermal route is one of the most common means of drug delivery that is minimally invasive. The products used for this are microneedles or microarray patches (MAPs), which painlessly puncture the skin of the patient and access the epidermal/dermal layer. In 2022, the DeSimone Laboratory of the University of Virginia School of Medicine (U.S.) developed a high-resolution continuous liquid interface production (CLIP) 3D printing technology, which uses light and oxygen to enable a continuous, noncontact polymerization dead zone at the build surface, which allows for the rapid production of MAPs with precise and tunable geometries.
China Microarray Market Opportunity
Advancements in Microarray Technologies
Some of the recent advancements in the microarray techniques are as follows:
-
In August 2024, CapitalBio Technology Co., Ltd. (China) launched the Chromosome Microarray (CMA) Detection 2.0 microarray chips to investigate chromosomal factors that cause miscarriages and abnormalities.
-
In August 2023, Thermo Fisher Scientific, Inc. (U.S.) launched a chromosomal microarray to improve cytogenic research lab productivity, efficiency, and profitability. This is in response to the growing demand for laboratory services and the ongoing shortage of laboratory professionals.
Such developments in microarray technology provide several benefits, such as personalized services for patients according to their condition, rapid and accurate results, and high-quality data. These advancements can be applied in various aspects of the research and diagnostic field, such as clinical trials, research studies, biomarker discovery, and diagnosis and treatment of diseases, supporting market growth.
China Microarray Market Study: Key Findings
The Consumables Segment to Account for the Largest Share of this Market in 2024
Based on product, the China microarray market is segmented into instruments, consumables, software, and services. In 2024, the consumables segment is expected to account for the largest share of 62.6% of the China microarray market. The substantial market share of this segment is due to the increasing incidence of cancer, wide application areas of microarray technology, rising funding for genomic R&D, and growing research for personalized medicine.
Furthermore, the consumables segment is slated to register the highest CAGR of 9.2% during the forecast period. The increased volume of testing for chronic diseases and the rising awareness among the general population about testing and disease awareness drive this segment's growth.
The Drug Discovery & Development Segment to Account for the Largest Share of this Market in 2024
Based on application, the China microarray market is segmented into drug discovery & development, research applications, diagnostics, and other applications. In 2024, the drug discovery & development segment is expected to account for the largest share of 51.7% of the China microarray market. The large market share is due to the growing public and private investments in pharma and biotech R&D and initiatives by the pharmaceutical and biotechnology companies to expand their research capabilities by opening new research centers and launches of new and innovative microarray technologies.
Moreover, the research applications segment is expected to record the highest CAGR of 9.2% during the forecast period. The high sensitivity of microarray technologies, low sample volume requirements, and cost-effectiveness drive this segment's growth.
The Pharmaceutical and Biotechnology Companies Segment to Account for the Largest Share of this Market in 2024
Based on end user, the China microarray market is segmented into pharmaceutical and biotechnology companies, contract research organizations (CROs), research and academic institutes, hospitals & diagnostic laboratories, and other end users, which includes veterinary clinics, the agricultural industry, and forensic laboratories. In 2024, the pharmaceutical and biotechnology companies segment is expected to account for the largest share of the China microarray market. This segment's substantial market share is due to high pharmaceutical R&D expenditure, rising demand for new drug discovery & development, increasing funding, grants, and investments for genomic research, and growing focus on increasing overall productivity. The rising demand for drug discovery coupled with the rising R&D expenditure will increase the demand for techniques such as microarray technology that offer accurate results and provide better and vast information.
Moreover, the contract research organizations (CROs) segment is projected to record the highest CAGR during the forecast period.
China Microarray Market: Key Companies
The report includes a competitive landscape based on an extensive assessment of the key growth strategies adopted by leading market participants over the past three to four years. The key players profiled in China microarray market report are Sino Biological, Inc. (China), CapitalBio Technology Co., Ltd. (China), Arrayit Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Illumina, Inc. (U.S.), Revvity, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Merck KGaA (Germany), and Qiagen N.V. (Netherlands), and RayBiotech Life, Inc. (U.S.).
China Microarray Market Industry Overview: Latest Developments from Key Industry Players
-
In January 2024, Thermo Fisher Scientific, Inc. (U.S.) launched the Axiom PangenomiX Array, which offers optimal genetic coverage for population-scale disease studies and pharmacogenomics research.
-
In January 2024, Bristol Myers Squibb (BMS) (U.S.), Glaxo Smith Kline plc (GSK) (U.K.), and Novo Nordisk (Denmark) joined the Alliance for Genomic Discovery headed by Illumina to co-fund the whole-genome sequencing (WGS) of 250,000 DNA samples. The alliance also aims to gain access to the resulting data for use in drug discovery and therapeutic development.
-
In September 2022, Thermo Fisher Scientific, Inc. (U.S.) partnered with the Taiwan Precision Medicine Initiative (TPMI) to conduct a large-scale predictive genomics study and genotype 1 million people in Taiwan.
Need data on specific countries or regions?
Customize this report for countries of interest.
China Microarray Market Research Summary
|
Particulars |
Details |
|
Page No |
109 |
|
Format |
|
|
Forecast Period |
2024-2031 |
|
Base Year |
2023 |
|
CAGR |
8.4% |
|
Market Size (Value) |
$910.4 million by 2031 |
|
Segments Covered |
By Product
By Application
By End User
|
|
Countries Covered |
China |
|
Key Companies |
Sino Biological, Inc. (China), CapitalBio Technology Co., Ltd. (China), Arrayit Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Illumina, Inc. (U.S.), Revvity, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Merck KGaA (Germany), and Qiagen N.V. (Netherlands), and RayBiotech Life, Inc. (U.S.) |
Key questions answered in the report china microarray market:
The China microarray market report covers qualitative analysis and market sizing based on product and end user. It analyzes various segments of the China microarray market at the country level and offers insights on factors impacting market growth, factor analysis, case studies, regulatory analysis, pricing analysis, and Porter’s five forces analysis.
The China microarray market is projected to reach $910.4 million by 2031, at a CAGR of 8.4% during the forecast period.
The consumables segment is expected to account for the largest share of the China microarray market in 2024. Factors such as the high burden of diseases, the high adoption of microarray kits, and the presence of initiatives supporting disease diagnosis support this segment's largest share.
Based on the application, the research application segment is projected to create more traction.
Based on end user, the contract research organizations segment is projected to register the highest growth during the forecast period.
The expanding research applications of microarrays, increasing genomics and proteomics research activities, the rising prevalence of cancers and genetic disorders, and growing R&D investments by the pharmaceutical and biotechnology sectors are factors supporting the growth of this market. Furthermore, advancements in microarray technology and the growing adoption of personalized medicine are anticipated to offer significant growth opportunities for companies operating in this market.
Author Name:
According to this latest publication from Meticulous Research®, the China microarray market is expected to register a CAGR of 8.4% from 2024 to 2031 to reach $910.4 million by 2031.
The growth of the China microarray market is driven by the increasing research applications of microarray, growth in genomics & proteomics research, rising prevalence of cancers & genetic disorders, and growing R&D expenditures in the pharmaceutical & biotechnology industries. However, the elevated costs of microarray compared to other genetic testing methods and the growing utilization of next-generation sequencing technology restrain the market growth.
Advancements in microarray technologies are expected to offer lucrative opportunities for the market players. However, the lack of sensitivity and accuracy in microarray are major challenges to the market's growth.
The overview of the top 10 players in the market is as below:
Thermo Fisher Scientific, Inc. (U.S.)
Founded in 1956 and headquartered in Massachusetts, U.S., Thermo Fisher Scientific, Inc. offers products and services in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, government, and academic sectors. The company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products & Pharma Services.
The company provides microarray through its Life Sciences Solutions segment, which includes reagents, instruments, and consumables used in biological & medical research, drug or vaccine discovery & production, and infection or disease diagnosis. These products and services are used in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, and academic markets. Life Sciences Solutions includes three primary businesses: Biosciences, Genetic Sciences, and Bioproduction.
Thermo Fisher has a geographical presence across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa through its subsidiaries, R&D sites, and distribution network. As of December 2023, the company had a headcount of 122,000 employees, of which 20,000 were employed in Asia-Pacific.
Some of its major subsidiaries are Thermo Fisher Scientific (China) Holding Limited, Thermo Electron (Shanghai) Management Co., Ltd., National HyClone (Lanzhou) Bio-engineering Co., Ltd., Fisher Laboratory Products Manufacturing (Shanghai) Co., Ltd, Fisher Scientific Worldwide (Shanghai) Co., Ltd., Scientific Products (Shanghai) Pte. Ltd., and Oxoid (Microbiology (Beijing) Co., Ltd.
Illumina, Inc. (U.S.)
Incorporated in 1998 and headquartered in California, U.S., Illumina, Inc. provides sequencing and array-based solutions for genomic and genetic analysis. The company operates through two reportable segments: Core Illumina and GRAIL.
Illumina caters to a diverse clientele, including government laboratories, genomic research centers, academic institutions, hospitals, commercial molecular diagnostics laboratories, and pharmaceutical and consumer genomics companies. The company operates a manufacturing facility in Shanghai, China, and manages distribution through its subsidiaries: Illumina (China) Scientific Co., Ltd., Illumina (China) Scientific Co., Ltd. – Beijing Branch, Illumina (China) Scientific Co., Ltd. – Guangzhou, Illumina Trading (Shanghai) Co., Ltd., and Illumina Diagnostics (Shanghai) Co., Ltd.
Founded in 1668 and headquartered in Darmstadt, Germany, Merck KGaA is a science and technology firm that creates products and services targeted at specific therapeutic areas, including allergies, fertility, oncology, and neurodegenerative diseases. The company develops pharmaceuticals, diagnostic agents, and medical devices and offers solutions that support biotechnology and pharmaceutical research. Additionally, Merck KGaA supplies specialty chemicals for diverse applications, such as materials for integrated circuits, liquid crystals for electronic displays, effect pigments for coatings and color cosmetics, and functional materials for energy solutions.
The company operates across three reportable business segments: Healthcare, Life Sciences, and Performance Materials. The Life Sciences segment is subdivided into three categories: Science and Lab Solutions, Process Solutions, and Life Science Services. Within its Life Sciences segment, the company is active in the microarray market, providing a range of solutions such as filtration, chromatography, process development, and manufacturing to support the development and production of biologics-based drugs.
The company maintains manufacturing facilities in the U.S., China, Germany, and Switzerland. Notable subsidiaries include Merck Chemical Co. Ltd., Merck Chemicals (Shanghai) Co., Ltd., Merck Life Science Technologies (Nantong) Co., Ltd., Merck Pharmaceutical Manufacturing (Jiangsu) Co., Ltd., and Sigma-Aldrich (Wuxi) Life Science & Technology Co., Ltd., all based in China.
Agilent Technologies, Inc. (U.S.)
Founded in 1999 and headquartered in California, U.S., Agilent Technologies, Inc. provides application-based solutions to the life sciences, diagnostics, and applied chemical markets. The company operates through three reportable segments: Life Sciences and Applied Markets, Agilent Cross Lab, and Diagnostics & Genomics. It operates in the microarray market through the Diagnostics & Genomics segment.
The Diagnostics & Genomics segment operates in eight main areas of work: pathology products, specific proteins and flow cytometry reagents, companion diagnostics, target enrichment, cytogenic research solutions and microarray, qPCR instrumentation and molecular biology reagents, nucleic acid solutions, automated electrophoresis, and microfluidics solutions.
Agilent offers services through its subsidiaries and a strong distribution network in Brazil, Canada, China, Mexico, Austria, Belgium, Finland, Germany, Ireland, Israel, Netherlands, Spain, Japan, South Korea, and India. The company has R&D and manufacturing sites in California, Colorado, Delaware, Massachusetts, Texas, Vermont, and Washington in the U.S., and Australia, China, Denmark, Germany, Italy, Japan, Malaysia, Singapore, and the U.K. Some of the company’s subsidiaries operating in China are Agilent Technologies Co. Ltd (China), Agilent Bioscience Co. Ltd (Hangzhou), Agilent Technologies Shanghai Co. Ltd (Shanghai), and Agilent Technologies Hong Kong Ltd. (Hong Kong).
Formed in 2023 and headquartered in Massachusetts, U.S., Revvity, Inc. is a multinational company that offers products, solutions, and services for the life sciences, diagnostics, and applied markets. It operates through two reportable segments: Life Sciences and Diagnostics. The company operates in the microarray market through the Diagnostics segment. In May 2023, the company was rebranded from PerkinElmer, Inc. to Revvity, Inc.
The company’s manufacturing and R&D facilities are in several countries, including the U.S., China, Japan, and Germany. In addition, it has a strong network of sales and marketing channels and service personnel in over 38 countries and sells its products and services in over 190 countries.
Revvity, Inc. sells its products and services predominantly through its distributors. Some of its subsidiaries operating in China are Beijing OUMENG Biotechnology Co., Ltd. (China), BioLegend (Shenzhen) Ltd. (China), BioLegend China (Beijing) Ltd. (China), PerkinElmer Instruments (Shanghai) Co. Ltd. (China), Guangzhou EUROIMMUN Medical Diagnostic Products Co., Ltd. (China), Revvity Biomed (Shanghai) Co., Ltd., and Oxford Immunotec (Shanghai) Medical Device Co. Ltd., among others.
Qiagen N.V. (Netherlands)
Founded in 1984 and headquartered in Venlo, the Netherlands, QIAGEN N.V. provides sample and assay technologies for molecular diagnostics, applied testing, and academic and pharmaceutical research. The company offers its products through only one reportable segment and in two major markets: Molecular Diagnostics and Life Sciences. It provides microarray products through this segment.
Qiagen’s product portfolio encompasses diagnostic solutions, PCR products, genomic or NGS products, consumables, and instruments for sample technologies. Additionally, the company provides over 500 core products, which include instruments, kits, bioinformatics solutions, and a diverse array of NGS services. These services cover RNA sequencing, DNA sequencing, whole genome amplification, and RNA isolation.
The company markets products in more than 130 countries worldwide. It has facilities in the U.S., China, Germany, Poland, the Philippines, Denmark, Romania, Spain, the U.K., and other countries. Furthermore, the company's sales are handled by distributors and subsidiaries. Some of the company's key subsidiaries operating in China are QIAGEN China (Shanghai) Co. Ltd. (China).
Founded in 2007 and headquartered in Beijing, China, Sino Biological, Inc. is an international reagent supplier and technical contract service provider. The company provides various products and solutions such as antibodies, proteins, cytokine and growth factor solutions, organoid research solutions, influenza vaccine solutions, CAR-T therapy solutions, ELISA kits, Cytokine ELISA kits, and viral reagents banks.
They also provide high-quality, independently developed recombinant proteins, antibodies, and cDNA clones for basic, translational, and clinical research. The company has approximately 8,000 proteins, 14,000 antibodies, 45,000 gene products, and 600 ELISA kits, along with its progressive technology platforms. Its headquarters are in Beijing, China, and it has subsidiaries in the U.S., Europe, Japan, Suzhou, Taizhou, and China and branches in Shanghai and Guangzhou.
CapitalBio Technology Co., Ltd. (China)
Founded in 2000 and headquartered in Beijing, China, CapitalBio Technology Co., Ltd. is the industrialized platform of the CapitalBio Corporation and the Beijing National Engineering Research Center for Biochips. The company develops molecular detection products for hereditary diseases, infectious diseases, tumors, individualized medicine, disease susceptibility gene detection, and other urgently needed clinical products.
CapitalBio, leveraging a comprehensive biotechnology platform, offers a range of products and services, including instruments and equipment, supporting reagents and consumables, scientific research service outsourcing, and integrated experimental solutions. The company has developed a series of molecular detection products targeting hereditary diseases, infectious diseases, tumors, personalized medicine, disease susceptibility gene detection, and other critical clinical needs. Additionally, CapitalBio provides product services and comprehensive solutions for precise diagnosis and health management.
The company exports its products to approximately 30 countries and regions in North America, Europe, and Asia, among others. It also partners with companies across regions, such as Thermo Fisher Scientific, Inc. (U.S.) and F. Hoffmann-La Roche Ltd. (Switzerland).
Founded in 1997 and headquartered in California, U.S., Arrayit Corporation is a life sciences company that specializes in microarray technology. Its products include microarray e-chips, microarray flex chips, peptide microarray, protein microarray, and custom microarray, among others. The company also provides services such as microarray services, microarray scanning, reverse-phase microarray, and microarray printing. Its clientele includes university laboratories, government laboratories, biotechnology companies, life sciences companies, clinical laboratories, pharmaceutical companies, and hospitals worldwide. The company provides its products through its distributors in China, such as Beijing Biocreative Technology Co., LTD. (China) and Gene Company Limited (China).
Arrayit Corporation provides microarray tools to life sciences researchers, enabling them to develop new clinical tests, safer medicines, and better crop plants in biomedicine and agriculture.
RayBiotech Life, Inc. (U.S.)
Founded in 2001 and headquartered in Georgia, U.S., RayBiotech Life, Inc. is a life sciences company specializing in protein research. It offers a range of protein research kits, reagents, and services aimed at advancing proteomic research. The company develops innovative array technologies, high-performance single-protein analysis tools, and quality-focused services to facilitate the discovery of disease-related protein biomarkers, identify new drug targets, and advance personalized medicine.
The company holds GMP, GLP, and ISO 13485 certifications and employs over 150 people. It offers a diverse range of products and services, including arrays, ELISA kits, antibodies, proteins and peptides, assay kits, and flow cytometry reagents. Its services encompass microarray services, ELISA services, antibody services, protein expression and purification services, CRO services, and additional offerings. In the China microarray market, the company provides protein arrays, proteome profiling arrays, and post-translational modification arrays.
Some of the company's distributors in China include RayBiotech Guangzhou Co., Ltd., Guangxi Tainuo Bioengineering Co., Ltd., Wayen Biotechnologies (Shanghai), Inc., Daoke Medicine Technology (Shanghai) Co., Ltd., Tianjin WoSunBio Technology Co., Ltd., GanSu Red Biotech Co., Ltd., Shenyang Huibai Biological Technology Co., Ltd., Shanghai Mai Bio Co., Ltd., Shanghai Jiayuan Biological Technology, Inc., Shanghai Biotend Biological Technology Co., Ltd., and Chongqing Borke Biotechnology Co., Ltd., among others.
Popular Mentions – Sakura Finetek USA, Inc. (U.S.), Dextra Laboratories Ltd. (U.K.), GeneCopoeia, Inc. (U.S.), Takara Bio USA, Inc. (U.S.), and Sysmex Corporation (Japan), among others.
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
Published Date: Oct-2024
Published Date: Aug-2024
Published Date: Mar-2019
Published Date: Jan-2024
Published Date: Oct-2013
